Summary
Transitional cell carcinoma of the bladder is one of the human cancers most responsive to immunotherapy, and local interleukin-2 (IL-2) production appears to be an important requirement for immunotherapy to be effective. In this study, we engineered two human bladder cancer cell lines (RT112 and EJ) to constitutively release human IL-2 by retroviral vector-mediated gene transfer. Following infection and selection, stable and consistent production of biologically active IL-2 was demonstrated at both the mRNA and the protein level. Morphology, in vitro growth rate and proliferation, as well as other cytokine gene mRNA or membrane adhesion receptor expression, were not altered in IL-2 transduced cells as compared to their parental or control vector-infected counterparts. Moreover, IL-2 engineered cells lost their tumorigenicity into nu/numice and the mechanism of rejection appeared to involve multiple host effector cell populations, among which a prominent role was played by neutrophils and radiosensitive cells. These findings may offer support to the development of an IL-2-based gene therapy approach to human bladder cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alosco, T., Croy, B. A., Gansbacher, B., Wang, H. Q., Rao, U. & Bankert, R. (1993). Anti-tumour response independent of functional B and T lymphocytes induced by the local and sustained release of interleukin-2 by the tumour cell. Cancer Immunol Immunother 36: 364–372.
Bass, C., Cabrera, G., Elgavish, A., Robert, B., Siegal, G. P., Anderson, S. C., Maneval, D. C. & Curiel, D. T. (1995). Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 2: 97–104.
Cavallo, F., Giovarelli, M., Gulino, A., Vacca, A., Stoppacciaro, A., Modesti, A. & Forni, G. (1992). Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to non-immunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 149: 3627–3635.
Chomczynski, P. & Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159.
Cignetti, A., Guarini, A., Carbone, A., Forni, M., Cronin, K., Forni, G., Gansbacher, B. & Foà, R. (1994). Transduction of the IL-2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL-2 expression. J Natl Cancer Inst 86: 785–791.
Colombo, M. P., Modesti, A., Parmiani, G. & Forni, G. (1992). Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 52: 4853–4857.
Connor, J., Bannerji, R., Saito, S., Heston, W., Fair, W. & Gilboa, E. (1993). Regression of bladder tumours in mice treated with IL-2 gene-modified tumour cells. J Exp Med 177: 1127–1134.
Djeu, J. Y., Liu, J. H., Wei, S., Rui, H., Pearson, C. A., Leonard, W. J. & Blanchard, D. K. (1993). Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2. J Immunol 150: 960–70.
Dranoff, G. & Mulligan, R. C. (1995). Gene transfer as cancer therapy. Adv Immunol 58: 417–454.
Dusty Miller, A. & Rosman, G. J. (1989). Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 980–986.
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B. & Frost, P. (1990). Interleukin-2 production by tumour cells bypasses T helper function in the generation of an anti-tumour response. Cell 60: 397–403.
Forni, G., Cavallo, G. P., Giovarelli, M., Benetton, G., Jemma, C., Barioglio, M. G., De Stefani, A., Forni, M., Santoni, A., Modesti, A., Cavallo, G., Menzio, P. & Cortesina, G. (1988). Tumor immunotherapy by local injection of interleukin-2 and non-reactive lymphocytes. Experimental and clinical results. Prog Exp Tumor Res 32: 187–212.
Gansbacher, B., Zier, K., Cronin, K., Hantzopoulos, P. A., Bouchard, B., Houghton, A., Gilboa, E. & Golde, D. (1992). Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood 80: 2817–2825.
Gastl, G., Finstad, C. L., Guarini, A., Golde, D., Bosl, G., Bander, N. H., Gilboa, E. & Gansbacher, B. (1992). Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52: 6229–6236.
Girard, D., Gosselin, J., Heitz, D., Paquin, R. & Beaulieu, A. D. (1995). Effects of interleukin-2 on gene expression in human neutrophils. Blood 86: 1170–1176.
Guarini, A., Gansbacher, B., Cronin, K., Fierro, M. T. & Foà, R. (1995). IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific anti-tumour cytotoxic T-lymphocyte response. Cytokines Mol Ther 1: 57–64.
Guarini, A., Riera, L., Reato, G., Carbone, A., Cignetti, A., Gillio Tos, A., Lanfrancone, L., Melani, C., Paul, R. W., Forni, G. & Foà, R. (1996). Human lung carcinoma cells engineered to release IL-2, IL-7, GM-CSF, and TNF-α: growth in nu/nu mice and modulation of TGF-β 1 production. Int J Oncol 8: 765–772.
Guarini, A., Riera, L., Cignetti, A., Montacchini, L., Massaia, M. & Foà, R. (1997). Transfer of the interleukin-2 gene into human cancer cells induces specific anti-tumour recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood 89: 212–218.
Hara, I., Nguyen, H., Takechi, Y., Gansbacher, B., Chapman, P. B. & Houghton, A. N. (1995). Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer 61: 253–260.
Hathorn, R. W., Tso, C. L., Kaboo, R., Pang, S., Figlin, R., Sawyers, C., deKernion, J. B. & Belldegrun, A. (1994). In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-α gene transfer. Cancer 74: 1904–1911.
Hawkyard, S. J., Jackson, A. M., Prescott, K. J. & Chisholm, G. D. (1993). The effect of recombinant cytokines on bladder cancer cells in vitro. J Urol 150: 514–518.
Hicks, C., Cooley, M. A. & Penny, R. (1991). Investigation of interleukin-2 receptors on human endothelial cells. Growth Factors 5: 201–208.
Liu, J. H., Wei, S., Ussery, D., Epling-Burnette, P. K., Leonard, W. J. & Djeu, J. Y. (1994). Expression of interleukin-2 receptor gamma chain on human neutrophils. Blood 84: 3870–3875.
Lum, B. L. & Torti, F. M. (1995). Immunotherapy and the prospects for immunologic-based gene therapy in superficial bladder cancer. FORUM Trends Exp Clin Med 5: 410–439.
Masters, J. R. W., Hepburn, P. J., Walker, L., Highman, W. J., Trejdosiewicz, L. K., Povey, S., Parkar, M., Hill, B. T., Riddle, P. R. & Franks, L. M. (1986). Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 46: 3630–3636.
Meazza, R., Marciano, S., Sforzini, S., Orengo, A. M., Coppolecchia, M., Musiani, P., Ardizzoni, A., Santi, L., Azzarone, B. & Ferrini, S. (1996). Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small cell lung cancer. Br J Cancer 74: 788–795.
Melani, C., Chiodoni, C., Arienti, F., Maccalli, C., Sule-Suso, J., Anichini, A., Colombo, M. P. & Parmiani, G. (1994). Cytokine gene transduction in tumour cells: IL-2 or IL-4 gene transfer in human melanoma cells. Nat Immun Cell Growth Regul 13: 76–94.
Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M. P., Lollini, P. L. & Forni, G. (1997). Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 18: 32–36.
Nista, A., Mattioni, M., Gismondi, A., Palmieri, G. & Santoni, A. (1996). β1 integrin expression and function in human bladder cancer cells: modulation by TNFα. Anticancer Res 16: 581–588.
Okamoto, M., Hattori, K. & Oyasu, R. (1997). Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 72: 149–194.
Pericle, F., Kirken, R. A., Epling-Burnette, P. K., Blanchard, D. K. & Djeu, J. Y. (1996). Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int J Cancer 66: 367–373.
Sette, A., Adorini, L., Marubini, E. & Doria, G. (1986). A microcomputer program for probit analysis of interleukin-2 (IL-2) titration data. J Immunol Methods 75: 34–40.
Sitkovsky, M. V. & Paul, W. E. (1988). Immunology. Global or directed exocytosis? Nature 332: 306–307.
Stein, U., Walther, W. & Shoemaker, R. H. (1996). Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 88: 1383–1392.
Tubaro, A., Velotti, F., Stoppacciaro, A., Santoni, A., Vicentini, C., Bossola, P. C., Galassi, P., Pettinato, A., Morrone, S., Napolitano, T., Frati, L., Ruco, L., Franks, C. R., Palmer, P. A., Pourreau, C. N. & Miano, L. (1991). Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer. Cancer 68: 56–61.
Tubaro, A., Stoppacciaro, A., Velotti, F., Bossola, P. C., Cusumano, G., Vicentini, C., De Carli, P., Ruco, L., Santoni, A., Cancrini, A., Giuffrida, A. M., Cippitelli, M., Palmer, P. A. & Miano, L. (1995). Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2. Eur Urol 28: 297–303.
Velotti, F., Stoppacciaro, A., Ruco, L., Tubaro, A., Pettinato, A., Morrone, S., Napolitano, T., Bossola, P. C., Franks, C. R., Palmer, P. A., Pourreau, C. N., Piccoli, M., Baroni, C. D., Frati, L., Miano, L. & Santoni, A. (1991a). Local activation of immune response in bladder cancer patients treated with intra-arterial infusion of recombinant interleukin-2. Cancer Res 51: 2456–2462.
Velotti, F., Stoppacciaro, A., Tubaro, A., Giuffrida, A., Morrone, S., Ruco, L., Vicentini, C., Tonelli, V. H., Miano, L. & Santoni, A. (1991b). Immune response in bladder cancer patients (pts) treated with two different recombinant interleukin-2 (rIL-2) local/regional regimens. Proc Am Ass Cancer Res, (abstract 246)
Velotti, F., Cippitelli, M., Giuffrida, A. M., Punturieri, A., Moretti, F., Stoppacciaro, A., Tubaro, A., De Maria, R. & Santoni, A. (1994). Local immunotherapy of human bladder cancer with recombinant IL-2: activation of immune response and possible direct action of IL-2 on tumour cells. In Cytokine-induced Tumour Immunogenicity. From Exogenous Molecules to Gene Therapy, Forni G, Foà R, Santoni A, Frati L (eds), pp. 429–422, Academic Press London
Verstovsek, S., MacCubbin, D., Ehrka, M. J. & Mihich, E. (1992). Tumoricidal activation of murine resident peritoneal macrophages by interleukin-2 and tumor necrosis factor α. Cancer Res 52: 3880–3885.
Xu, H., Zhou, Y., Seigne, J., Perng, G., Mixon, M., Zhang, C., Li, J., Benedict, W. F. & Hu, S. (1996). Enhanced tumour suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 56: 2245–2249.
Yasumura, S., Lin, W. C., Weidmann, E., Hebda, P. & Whiteside, T. L. (1994). Expression of interleukin-2 receptors on human carcinoma cell lines and tumour growth inhibition by interleukin-2. Int J Cancer 59: 225–234.
Wei, S., Blanchard, D. K., Liu, J. H., Leonard, W. J. & Djeu, J. Y. (1993). Activation of tumor necrosis factor-alpha production from human neutrophils by IL-2 via IL-2-R beta. J Immunol 150: 1979–1987.
Wei, S., Liu, J. H., Blanchard, D. K. & Djeu, J. Y. (1994). Induction of IL-8 gene expression in human polymorphonuclear neutrophils by recombinant IL-2. J Immunol 152: 3630–3636.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Milella, M., Jacobelli, J., Cavallo, F. et al. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. Br J Cancer 79, 770–779 (1999). https://doi.org/10.1038/sj.bjc.6690124
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690124
Keywords
This article is cited by
-
Pembrolizumab plus enfortumab vedotin in urothelial cancer
Nature Reviews Urology (2024)
-
Immune gene therapy in urology
Current Urology Reports (2002)
